- Home
- INZY vs BMEA Comparison
INZY vs BMEA Comparison
Compare INZY & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- BMEA
- Stock Information
- Founded
- INZY 2015
- BMEA 2017
- Country
- INZY United States
- BMEA United States
- Employees
- INZY N/A
- BMEA N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- INZY Health Care
- BMEA Health Care
- Exchange
- INZY Nasdaq
- BMEA Nasdaq
- Market Cap
- INZY 64.9M
- BMEA 65.8M
- IPO Year
- INZY 2020
- BMEA 2021
- Fundamental
- Price
- INZY $1.15
- BMEA $1.63
- Analyst Decision
- INZY Strong Buy
- BMEA Strong Buy
- Analyst Count
- INZY 9
- BMEA 11
- Target Price
- INZY $17.22
- BMEA $27.60
- AVG Volume (30 Days)
- INZY 1.1M
- BMEA 714.3K
- Earning Date
- INZY 05-20-2025
- BMEA 05-05-2025
- Dividend Yield
- INZY N/A
- BMEA N/A
- EPS Growth
- INZY N/A
- BMEA N/A
- EPS
- INZY N/A
- BMEA N/A
- Revenue
- INZY N/A
- BMEA N/A
- Revenue This Year
- INZY N/A
- BMEA N/A
- Revenue Next Year
- INZY N/A
- BMEA N/A
- P/E Ratio
- INZY N/A
- BMEA N/A
- Revenue Growth
- INZY N/A
- BMEA N/A
- 52 Week Low
- INZY $0.72
- BMEA $1.53
- 52 Week High
- INZY $6.24
- BMEA $13.43
- Technical
- Relative Strength Index (RSI)
- INZY 50.96
- BMEA 37.94
- Support Level
- INZY $1.18
- BMEA $1.61
- Resistance Level
- INZY $1.63
- BMEA $2.30
- Average True Range (ATR)
- INZY 0.20
- BMEA 0.21
- MACD
- INZY 0.02
- BMEA -0.01
- Stochastic Oscillator
- INZY 23.66
- BMEA 3.11
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.